Zydus Lifesciences soars on inking pact with Apollo Hospitals to expand access to Shield MCD test in India
Zydus Lifesciences is currently trading at Rs. 1133.75, up by 34.10 points or 3.10% from its previous closing of Rs. 1099.65 on the BSE.
The scrip opened at Rs. 1121.45 and has touched a high and low of Rs. 1136.05 and Rs. 1103.80 respectively. So far 110495 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1,136.05 on 03-Jul-2026 and a 52 week low of Rs. 835.85 on 02-Apr-2026.
Last one week high and low of the scrip stood at Rs. 1,136.05 and Rs. 1095.35 respectively. The current market cap of the company is Rs. 113211.70 crore.
The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 18.15% and 6.86% respectively.
Zydus Lifesciences has inked a Memorandum of Understanding with Apollo Hospitals to expand access to the Shield Multi-Cancer Detection test (MCD) in India. The company and Guardant Health Inc., a leading precision oncology company, have an exclusive agreement to make the Shield MCD test available in India.
The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types including bladder, colorectal, breast, prostate, oesophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older and who are at typical average risk for cancer. With just a blood draw, the test screens for 10 of the most common cancers, many of which have high mortality rates in India. The test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), recognising its potential to provide more effective screening for cancers than existing options.
